Skip to main content

Table 3 Least-squares mean percentage breast density by menopausal and HRT status

From: Genetic determinants of mammographic density

  

Postmenopausal/HRT status*

 

Genotype

Premenopausal* mean (n)

Never and past use mean (n)

Current use** mean (n)

P ***

CYP17

    

   A1/A1

34.0 (58)

31.9 (26)

37.9 (39)

 

   A1/A2

35.7 (94)

30.5 (33)

38.6 (52)

 

   A2/A2

37.9 (24)

24.9 (8)

48.6 (13)

 

P trend

0.39

0.42

0.16

0.13

COMT

    

   Val/Val

36.9 (62)

29.7 (20)

33.7 (39)

 

   Val/Met

34.4 (70)

31.6 (40)

42.3 (46)

 

   Met/Met

34.9 (44)

25.3 (7)

45.4 (19)

 

P trend

0.56

0.80

0.01

0.10

17HSDB1

    

   Gly/Gly

32.0 (52)

24.0 (13)

41.1 (32)

 

   Gly/Ser

35.5 (76)

33.7 (40)

39.4 (47)

 

   Ser/Ser

39.1 (48)

26.9 (14)

38.2 (25)

 

P trend

0.07

0.77

0.57

0.65

3HSDB1

    

   Asn/Asn

35.5 (106)

32.8 (42)

40.6 (61)

 

   Asn/Thr

33.4 (56)

25.8 (23)

40.8 (32)

 

   Thr/Thr

42.7 (14)

31.8 (2)

28.9 (9)

 

P trend

0.55

0.27

0.22

0.95

  1. *Adjusted for race, age, body mass index, parity, age at first birth, age at menarche and first-degree family history of breast cancer. **Current use of estrogen replacement therapy or estrogen plus progestin replacement therapy. *** P value for interaction between hormone replacement therapy (HRT) status (never used and past use versus current use) and genotype (ordinal).
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us